Nexalin Technology, the Nasdaq-listed neurostimulation device maker, has recommitted to its Uptown Houston base with a lease renewal and expansion at 1776 Yorktown, betting on physical footprint as it pushes a pivotal insomnia trial toward enrollment.
Thank you for your interest in The Registry. If you'd like to read further, you must Subscribe or Log In below to read the rest of this content.

Signup for news and special announcements!
You have successfully joined our subscriber list.
Dallas-based Lantern Asset Management has lined up a $150 million, five-year delayed-draw...
ByThe RegistryOctober 28, 2026Sam's Club will open its nearly 168,000-square-foot warehouse club at The Grand...
ByThe RegistryOctober 28, 2026Bedrock Robotics, the Waymo-alumni startup that retrofits excavators to dig without anyone...
ByThe RegistryOctober 28, 2026Dallas-Fort Worth topped the Urban Land Institute and PwC's Emerging Trends in...
ByThe RegistryOctober 28, 2026Error: Contact form not found.